App Enables Users to Track Brain Disorders on Their Smartphones
App Enables Users to Track Brain Disorders on Their Smartphones
Comments Off on App Enables Users to Track Brain Disorders on Their Smartphones
BINYAMINA, Israel People with chronic diseases are advised to stay home during the Covid-19 pandemic because they are at risk for complications should they become infected.
However, that makes it difficult to get essential medical monitoring for their existing conditions. And while Israel has emerged as a leader in telemedicine, it’s easier to check heart rate and blood pressure remotely than to evaluate from a distance what is happening in the brain.
Jan 13, 2021
Montfort’s FDA-cleared neurological monitoring is used by healthcare facilities on four continents and is tracking post-Covid symptoms in Brazil.
By Abigail Klein Leichman, ISRAEL21c
People with chronic diseases are advised to stay home during the Covid-19 pandemic because they are at risk for complications should they become infected.
However, that makes it difficult to get essential medical monitoring for their conditions. And while Israel has emerged as a world leader in telemedicine, it’s easier to check heart rate and blood pressure remotely than to evaluate from a distance what is happening in the brain.
Now, patients with neurological disorders can be monitored in real time remotely, with an FDA-approved solution from Israeli startup Montfort.
Share this article
Share this article
BINYAMINA, Israel, Dec. 16, 2020 /PRNewswire/ Montfort (Mon4t), an innovative medical startup introduces its real-time, remote neurological monitor.
Montfort s FDA-cleared solution leverages smartphone technology, big-data and AI to conduct digital neurological tests for patients with conditions such as Parkinson s disease, Huntington s disease, psychiatric disorders (like schizophrenia), as well as for patients with Post-COVID19 symptoms, some of which are similar to those observed in neurological conditions. About one billion people around the world suffer from neurological and psychiatric disorders. Diagnostics and treatment are based upon short and infrequent clinical visits thus limiting patients quality of care and increasing treatment costs - about 800 Billion USD in the US alone, says